Foster & Motley Inc. Lowers Holdings in Organon & Co. (NYSE:OGN)

Foster & Motley Inc. reduced its stake in shares of Organon & Co. (NYSE:OGN) by 10.4% during the 4th quarter, HoldingsChannel reports. The fund owned 33,111 shares of the company’s stock after selling 3,860 shares during the period. Foster & Motley Inc.’s holdings in Organon & Co. were worth $477,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Handelsbanken Fonder AB grew its stake in shares of Organon & Co. by 11.7% during the 4th quarter. Handelsbanken Fonder AB now owns 45,800 shares of the company’s stock valued at $660,000 after buying an additional 4,800 shares during the period. CWM LLC increased its stake in Organon & Co. by 8.3% during the fourth quarter. CWM LLC now owns 14,217 shares of the company’s stock worth $205,000 after acquiring an additional 1,087 shares during the last quarter. Signaturefd LLC raised its holdings in shares of Organon & Co. by 437.1% in the 4th quarter. Signaturefd LLC now owns 9,190 shares of the company’s stock worth $133,000 after purchasing an additional 7,479 shares during the period. Lindbrook Capital LLC raised its holdings in shares of Organon & Co. by 348.3% in the 4th quarter. Lindbrook Capital LLC now owns 1,838 shares of the company’s stock worth $27,000 after purchasing an additional 1,428 shares during the period. Finally, J.W. Cole Advisors Inc. acquired a new position in shares of Organon & Co. in the 4th quarter valued at about $188,000. Institutional investors and hedge funds own 77.43% of the company’s stock.

Analyst Ratings Changes

Separately, The Goldman Sachs Group raised their price target on shares of Organon & Co. from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Tuesday, February 20th.

Insider Buying and Selling

In other news, insider Kirke Weaver acquired 2,720 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was bought at an average cost of $18.36 per share, with a total value of $49,939.20. Following the transaction, the insider now directly owns 15,181 shares in the company, valued at approximately $278,723.16. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.17% of the stock is currently owned by insiders.

Organon & Co. Stock Performance

OGN stock opened at $18.71 on Thursday. The firm has a market cap of $4.78 billion, a P/E ratio of 4.68, a price-to-earnings-growth ratio of 0.88 and a beta of 0.83. Organon & Co. has a 1 year low of $10.84 and a 1 year high of $24.79. The stock has a 50-day simple moving average of $18.14 and a 200-day simple moving average of $15.67.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Thursday, February 15th. The company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.14. The firm had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.55 billion. Organon & Co. had a negative return on equity of 212.00% and a net margin of 16.33%. On average, equities research analysts predict that Organon & Co. will post 4.08 EPS for the current year.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 14th. Investors of record on Monday, February 26th were issued a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 5.99%. The ex-dividend date was Friday, February 23rd. Organon & Co.’s payout ratio is 28.00%.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.